Clinical Trial PCLX-001
Dr. John Mackey, Director of Clinical Trials at the Cross Cancer Institute, is leading a clinical research team to explore the new cancer biology and drug discovered by University of Alberta professor, Luc Berthiaume.
This new drug, called PCLX-001, shuts down the abnormal chemical signaling in many of the common cancers and triggers those cells to die, while sparing the normal healthy cells.
Current studies show that this drug has high activity and positive results in breast, lung, bladder, and pancreas cancers, but it is predicted to make the most significant difference – and potentially even a cure – in Non-Hodgkin Lymphomas, Leukemias, and other hematological cancers (blood cancers).
We want to help fund great research like this to help Albertans, and people everywhere, receive the treatment they need.
Your support will provide hope to people who would otherwise die of their cancer – despite all the best known treatments. You are giving people a better chance of a cancer-free outcome and more time with their families, friends, and loved ones.